Journal article
The blood proteome of imminent lung cancer diagnosis
D Albanes, K Alcala, N Alcala, CI Amos, AA Arslan, JK Bassett, P Brennan, Q Cai, C Chen, X Feng, ND Freedman, F Guida, RJ Hung, K Hveem, M Johansson, M Johansson, WP Koh, A Langhammer, RL Milne, D Muller Show all
Nature Communications | Published : 2023
Abstract
Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identify 36 proteins with independently reproducible associations with risk of imminent lung cancer diagnosis (all p < 4 × 10−5). These include a few markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) that have previously been reported in studies using pre-diagnostic blood samples for lung cancer. The 36 proteins include several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. This study was supported by the US NCI (INTEGRAL program U19 CA203654 and R03 CA245979), Fondation ARC pour la recherche sur le cancer and l'Institut National Du Cancer (INCa) (INCA201601246/ARC_10450, Fondation ARC et INCa, France), INCa (TABAC18-035, France), the Cancer Research Foundation of Northern Sweden (AMP19-962), an early detection of cancer development grant from Swedish Department of Health ministry, and Cancer Research UK [C18281/A29019]. RJH is supported by the Canada Research Chair of the Canadian Institute of Health Research. The Trondelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU), Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The Singapore Chinese Health Study was supported by the US National Institutes of Health Grant No. R01CA080205, R01CA144034 and UM182876. Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results Program. We thank the Biobank Research Unit at Umea University and Vaesterbotten Intervention Programme for providing data and samples, and acknowledge the contribution from Biobank Sweden, supported by the Swedish Research Council (VR 2017-00650). The coordination of EPIC was financially supported by Direction Generale de la Sante (French Ministry of Health) (Grant GR-IARC-2003-09-12-01), the European Commission (Directorate General for Health and Consumer Affairs), International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London with additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vaesterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution and ongoing support to the EPIC Study. We would like to thank Matthieu Foll and Lynnette Fernandez Cuesta at the International Agency for Research on Cancer (IARC/WHO) and Luis M. Montuenga at the University of Navarra for their valuable contributions to our understanding and interpretation of the results in this study.